Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17 USD | -1.45% | +0.18% | -45.45% |
30/04 | UBS Adjusts ACADIA Pharmaceuticals' Price Target to $27 From $33, Keeps Buy Rating | MT |
23/04 | Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-45.45% | 2.85B | |
+21.21% | 46.4B | |
-1.28% | 41.75B | |
+47.81% | 41.37B | |
-3.52% | 29.71B | |
+10.07% | 26.01B | |
-19.90% | 19.52B | |
+30.13% | 12.43B | |
+0.31% | 12.18B | |
-0.27% | 12.13B |
- Stock Market
- Equities
- ACAD Stock
- News ACADIA Pharmaceuticals Inc.
- Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating